Ionis Pharmaceuticals (NASDAQ:IONS) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.91) by 67.03 percent. This is a 67.74 percent increase over losses of $(0.93) per share from the same period last year. The company reported quarterly sales of $246.000 million which beat the analyst consensus estimate of $195.628 million by 25.75 percent. This is a 86.36 percent increase over sales of $132.000 million the same period last year.